Skip to main content
. 2021 Dec 23;9(12):e002843. doi: 10.1136/jitc-2021-002843

Figure 7.

Figure 7

Combination therapy with αPD-1 or αLAG-3 improved the antitumor efficacy of VV-scFv-TIGIT in colon cancer models (A) Treatment scheme of CT26 subcutaneous (S.C.) tumor model with VV and αPD-1. (B) Mean tumor volume of mice. (C) Individual tumor growth curve of mice. (D) Kaplan-Meier survival curves of tumor-bearing mice. (E) Treatment scheme of CT26 S.C. tumor model with VV and αLAG-3. (F) Mean tumor volume of mice. (G) Individual tumor growth curve of mice. (H) Kaplan-Meier survival curves of tumor-bearing mice. Tumor volume was measured every 2 days. Error bars represent SD. Once the tumor volume exceeded 2000 mm3, the mouse was considered dead. CR, complete remission; PR, partial remission; ns, no significant differences; *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001. PBS, phosphate-buffered saline; scFv, single-chain variable fragment; TIGIT, T-cell immunoglobulin and ITIM domain; VV, vaccinia virus.